Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forest Celexa

Executive Summary

"If Forest terminates Warner-Lambert's co-promotion agreement because of [a Warner-Lambert] merger, under no circumstances would Forest be obligated to make payments until 2004," Forest Chairman Howard Solomon says in a Jan. 27 letter to "The Pink Sheet." Warner-Lambert told a Jan. 19 teleconference that "even if there is that change of control and they exercise their option, there's a period of step down payments that take place through the balance of the six year agreement" (1"The Pink Sheet" Jan. 24, p. 14). Forest and Warner-Lambert are in discussions to end the co-promotion agreement for the antidepressant

Latest Headlines
See All
UsernamePublicRestriction

Register

PS035513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel